SCHEMBL22922181

SCHEMBL22922181

COC(=O)CCc1ccc(CCC(=O)OC)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP4F2 P78329 2/20 0.59
▸ CYP4A11 Q02928 2/20 0.59
▸ F2RL1 P55085 1/20 0.57
▸ TSHR P16473 2/20 0.55
▸ ADRB2 P07550 1/20 0.54
▸ ADRB1 P08588 1/20 0.54
▸ ALDH1A1 P00352 2/20 0.54
▸ LMNA P02545 1/20 0.54
▸ MAPT P10636 1/20 0.54
▸ HTT P42858 1/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ HSD17B10 Q99714 1/20 0.54
▸ IDO1 P14902 1/20 0.53
▸ TDP1 Q9NUW8 1/20 0.52
▸ EPHX2 P34913 1/20 0.51
▸ HRH3 Q9Y5N1 1/20 0.51
▸ CA12 O43570 1/20 0.50
▸ CA7 P43166 1/20 0.50
▸ CA9 Q16790 1/20 0.50
▸ CA14 Q9ULX7 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2569441 0.92 L3MBTL1 (0.55) CYP4F2CYP4A11F2RL1ADRB2ADRB1
SCHEMBL1587088 0.92 FFAR1 (0.59) CYP4F2CYP4A11F2RL1TSHRALDH1A1
SCHEMBL12419941 0.92 CYP4F2 (0.53) CYP4F2CYP4A11F2RL1TSHRADRB2
4-Hydroxyhydrocinnamic Acid Methyl Ester SCHEMBL95254 0.92 HDAC2 (0.53) CYP4F2CYP4A11F2RL1TSHRADRB2
SCHEMBL1410420 0.92 CYP4A11 (0.56) CYP4F2CYP4A11F2RL1TSHRADRB2
SCHEMBL8508610 0.92 CYP4F2 (0.53) CYP4F2CYP4A11F2RL1TSHRADRB2
SCHEMBL3679325 0.92 CYP4A11 (0.72) CYP4F2CYP4A11F2RL1TSHRADRB2
SCHEMBL11720060 0.90 CYP4F2 (0.50) CYP4F2CYP4A11F2RL1TSHRADRB2
SCHEMBL5567796 0.90 ADRB2 (0.51) CYP4F2CYP4A11F2RL1TSHRADRB2
SCHEMBL197699 0.90 CYP11B1 (0.58) CYP4F2CYP4A11F2RL1ADRB2ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118903087-A Functionalized long chain hydrocarbon mono-and dicarboxylic acids useful in the prevention or treatment of disease 埃斯佩尔维塔治疗股份有限公司 2024-11-08 — — CN disclosed
CN-114126593-B Functionalized long chain hydrocarbon mono-and dicarboxylic acids useful in the prevention or treatment of disease 埃斯佩尔维塔治疗股份有限公司 2024-07-26 — — CN disclosed
EP-4003314-B1 FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS USEFUL FOR THE PREVENTION OR TREATMENT OF DISEASE ESPERVITA THERAPEUTICS INC (US) 2024-07-10 — — EP disclosed
US-20230007838-A1 FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE ESPERVITA THERAPEUTICS, INC. 2023-01-12 — — US disclosed
US-20220402851-A1 FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE ESPERVITA THERAPEUTICS, INC. 2022-12-22 — — US disclosed
EP-4003314-A1 FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS USEFUL FOR THE PREVENTION OR TREATMENT OF DISEASE Espervita Therapeutics, Inc. (US) 2022-06-01 — — EP disclosed
US-11084773-B1 Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease ESPERVITA THERAPEUTICS, INC. (US) 2021-08-10 — — US disclosed
US-20210221765-A1 FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE ESPERVITA THERAPEUTICS, INC. 2021-07-22 — — US disclosed
WO-2021021563-A1 FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS USEFUL FOR THE PREVENTION OR TREATMENT OF DISEASE ESPERVITA THERAPEUTICS, INC. (US) 2021-02-04 — — WO disclosed
US-20210024447-A1 FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE ESPERVITA THERAPEUTICS, INC. 2021-01-28 — — US disclosed
CN-1376143-A Carboxylic acid derivatives and adhesion molecule inhibitors containing the same as the active ingredient TORAY INDUSTRIES (JP) 2002-10-23 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230007838-A1 FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE CPT1A, PPARG, PC CYP4F2 708/4885CYP4A11 659/4885F2RL1 1498/4885
US-20210221765-A1 FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE CPT1A, PPARG, PC CYP4F2 708/4885CYP4A11 659/4885F2RL1 1498/4885
US-11084773-B1 Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and their use for the prevention or treatment of disease CPT1A, PPARG, PC CYP4F2 708/4885CYP4A11 659/4885F2RL1 1498/4885
US-20210024447-A1 FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE CPT1A, PPARG, PC CYP4F2 708/4885CYP4A11 659/4885F2RL1 1498/4885
US-20220402851-A1 FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE CPT1A, PPARG, PC CYP4F2 708/4885CYP4A11 659/4885F2RL1 1498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback